Your Article Summary
See Latest ArticlesImpact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial
Gynecologic Oncology, 06/30/09
Markman M et al. - Twelve cycles of single agent maintenance paclitaxel significantly improves PFS. Explanations for the lack of a favorable influence on overall survival include: (a) treatment at relapse equalized outcome; (b) the sample size was insufficient to reveal a difference; (c) “crossover” of patients from 3 cycles to longer treatment masked a potential difference. An ongoing phase 3 trial will hopefully provide a definitive answer to the question of the impact of this maintenance strategy on overall survival.
Related Articles
Preventing future cancers by testing women with ovarian cancer for brca mutations
Journal of Clinical Oncology, 10/22/09
Relevance Score: 72%
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
British Journal of Cancer, 11/02/09
Relevance Score: 70%
Unusual Metals Could Forge New Cancer Drug
ScienceDaily, 10/20/09
Relevance Score: 70%
New Drug Aims To Seek And Destroy Many Types Of Cancer
ScienceDaily, 10/07/09
Relevance Score: 70%
New drug aims to seek and destroy many types of cancer
EurekAlert, 10/06/09
Relevance Score: 70%
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Colloid carcinoma of the intestinal type in the uterine cervix: Mucin immunohistochemistry
Pathology International, 12/17/09
The prevalence of abnormal cervical cytology in women with infertility
Diagnostic Cytopathology, 12/17/09
Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3
Cancer Immunology, Immunotherapy, 12/17/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: Results from a randomized phase II study
Palliative Medicine, 12/18/09
A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: An Eastern Cooperative Oncology Group Trial
Breast Cancer Research and Treatment, 12/17/09
Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer
Medical Oncology, 12/17/09